they are research observations in laboratory models
[2] Pharmacokinetic unknowns We lack good human pharmacokinetic data for injected GHK-Cu: how much intact complex survives in circulation, how much copper is handed off to plasma proteins, how much (if any) reaches the skin as functional complex, and what a safe cumulative copper exposure would be
But, they should talk to their oncologists first
The safer RUO focus is research documentation, COA review, peptide identity, peptide purity, HPLC, LC-MS, lot traceability, and RUO labeling
TB-500 (Thymosin Beta-4 fragment): Synthetic fragment corresponding to the LKKTET region of Thymosin Beta-4
The pricing confusion that surrounds it online, with numbers that vary by a factor of ten depending on the source, is not a reflection of what the therapy should cost